Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

How to Read a Research Peptide COA: Identity, Purity, Peptide Content, and Batch Traceability

Gloved laboratory researcher comparing a printed analytical report with an unbranded sample vial and procurement folder.

A research peptide certificate of analysis (COA) answers several different questions: which sample was tested, what identity evidence was obtained, how purity was measured, and what the content result means. Start with the sample-to-batch link, then read those results separately. A high purity percentage cannot answer all four questions.

This guide is for laboratory researchers and procurement teams. The published research example is from a synthetic-glucagon study, not a SaiyanMed batch report or a test performed for this article. It is an exercise in reading analytical records, not a guide to human or veterinary use.

Start with the sample and batch match

First establish whether the report belongs to the material you received. Compare the product name, lot number, and any declared fill against the label and procurement records. Where the laboratory uses a sample code instead of a supplier lot number, the submission record should connect the two.

That distinction matters. A laboratory may issue a genuine report for a submitted sample, yet the records supplied with a shipment may not link that sample to the delivered batch. Report authenticity and batch traceability need separate checks.

Keep the report number, version, sample receipt date, testing date, and issue date where available. An unexplained date or a mismatch is a reason to clarify the records before using the results—not, by itself, proof that a document is fraudulent.

Separate identity from purity

Generic chromatography and mass-spectrometry equipment beside a researcher reviewing analytical records.

Read an identity entry as a result from a particular method, not just a word such as “pass.” For a report listing mass spectrometry, look for the measured observation, the expected result, and the criterion used to compare them. If the summary only says “identity: conforms,” the supporting method or spectrum may be needed to understand that conclusion.

Purity is a different measurement. When a COA reports *chromatographic area percentage*, note the detector, integration basis, and peak assignment used by that method. An area-based result describes the distribution of integrated chromatographic signal; it is not automatically the fraction of the powder’s total mass represented by the target peptide. A multi-laboratory study of oxytocin compared HPLC assay against an external standard with quantitative NMR and amino acid analysis; the reference standard’s purity was assigned by mass balance. The comparison shows that an assay and a mass-balance value assignment are distinct methods, not universal reporting conventions.[1]

A useful identity review therefore has three parts: the stated material, the method’s result, and the acceptance criterion. A useful purity review adds the chromatogram and enough method information to explain how the percentage was obtained.

FDA describes Q2(R2) as a framework for analytical procedure validation in drug regulatory evaluation.[2] It is relevant background for discussing method performance, not evidence that a particular supplier method has been validated or a universal release standard for every research-use-only material.

Read peptide content as a separate result

Laboratory analyst reviewing a report beside a closed analytical balance and an unbranded sample vial.

The content entry needs a definition as well as a number. Is it the target peptide, total peptidic material, or a quantity reported on a corrected basis? What are the units, and which method produced the result?

A content result should specify the analyte, units, and calculation basis. A published mass-balance study shows why other sample components may need separate measurement.[3]

A published example: mass-balance assessment of synthetic glucagon

A study of one synthetic glucagon sample separately measured water by Karl Fischer titration, trifluoroacetic acid (TFA) by ion chromatography, inorganic ions by ICP-MS, and peptide-impurity sequences by Orbitrap mass spectrometry. After accounting for the measured components, the reported peptide content was 896.36 ± 0.68 mg/g for that sample.[3]

Field in the published study How to read it What remains unresolved
Material One synthetic glucagon sample The result does not describe a SaiyanMed product or another peptide.
Other measured components Water, TFA, inorganic ions, and peptide impurities were quantified separately Other reports may use different methods and components.
Peptide content: 896.36 ± 0.68 mg/g A mass-balance result for the analyzed sample It is not a universal correction factor or an HPLC area percentage.
Batch suitability Not established for other materials A separate batch-linked report and study-specific criteria are still needed.

This example demonstrates why peptide content and chromatographic area answer different questions. Its value is specific to the sample and methods in that study; it cannot be copied to another COA or used to accept or reject a batch.

The reading decision: record the material, method, units, and basis behind the result. If those are not clear, leave the interpretation unresolved rather than inferring content from an area-purity percentage.

This guide stops at interpreting the records; it does not reproduce preparation instructions or turn the example into a dosing calculation.

Check methods and laboratory scope

“Pass” is useful only when the applied specification is clear. Compare the reported result, units, and acceptance criterion with the requirements of your institution and study. Where a method reference is too brief, a supporting record may explain the detector, integration, calibration, or identity comparison. The summary COA need not reproduce every instrument setting.

Verify the issuer through an independently located laboratory website or contact channel. Check the original report or verification record where available, including its number and version. If the supplier issued the COA using an outside laboratory’s results, clarify which parts came from each organization.

Accreditation is another check, not a substitute for those records. ILAC explains how its Mutual Recognition Arrangement links accreditation bodies and supports acceptance of results from accredited conformity assessment bodies. Its directories can help locate laboratories accredited for particular activities.[4] For a specific claim, examine the laboratory location, current certificate, and scope covering the reported work—not just the presence of a logo.

Use a field-by-field COA review table

Use the table below to track what the report shows and what still needs verification. The follow-up depends on the report and the purpose of the study.

Report field What to record Follow-up when information is missing
Sample name and lot or laboratory code The identifier on the report and its connection to the received material Obtain the submission or procurement record that links the identifiers.
Report number, version, and dates Which document is being reviewed and when the recorded events occurred Confirm the applicable version and the meaning of unclear dates.
Identity Method, observed result, expected identity, and criterion Review supporting analytical data if the summary does not explain the conclusion.
HPLC or UPLC purity Percentage, detector, integration basis, and target-peak assignment Establish what the reported percentage measures.
Peptide content or assay Analyte, units, reporting basis, and method Clarify whether the result covers target peptide or total peptidic material.
Specification and laboratory scope Criteria applied and the relevant scope of any accreditation claim Compare with study requirements and verify the laboratory-specific records.
Tests not reported Attributes still required by the study Keep them unresolved until suitable evidence is available.

For example, if a genuine report uses a laboratory code that has no documented link to the delivered lot, record report authenticity checked; batch link unresolved. If identity is reported but the content basis is undefined, record identity evidence available; content interpretation unresolved. These are conditional review decisions, not findings from SaiyanMed reports.

What a COA cannot settle on its own

A chromatographic purity result, a mass-spectrometry result, or an accreditation mark alone does not establish sterility, endotoxin status, clinical safety or efficacy, regulatory approval, or suitability for your experiment. Nor does a report for one submitted sample establish results for every vial, batch, or later shipment.

Before accepting the documentation for a study, record three things: which material the report covers, what its tests support, and which required questions remain unanswered. Keep unresolved items visible rather than treating a high purity number as a substitute for missing evidence.

References

  1. Li et al. “Survey of peptide quantification methods and comparison of their reproducibility: A case study using oxytocin.” *Journal of Pharmaceutical and Biomedical Analysis* 166 (2019): 105–112.
  2. Q2(R2) Validation of Analytical Procedures — FDA
  3. Wang et al. “Purity determination of synthetic glucagon using a mass balance approach.” *Scientific Reports* 10 (2020): 4423.
  4. ILAC MRA and Signatories — International Laboratory Accreditation Cooperation

Research Use Only Disclaimer

Related research: How to Read a Peptide COA: Purity, Identity, Quantity and Red Flags; How to Read a Research Peptide COA: Identity, Purity, Peptide Content, and Batch Traceability; Peptide Identity Beyond the Product Name: Sequences, Fragments, Modifications, and Salt Forms; Peptide Stability Claims: What Batch-Specific Evidence Should Support Them.

Research Use Only: This article is intended for qualified laboratory researchers and provides general information on analytical documentation. It is not a validated experimental protocol and does not constitute medical, clinical, or veterinary guidance, diagnosis, or treatment advice. The SaiyanMed research materials discussed here are not intended for human or veterinary administration.